Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis

Hou, Haifeng; Chen, Zhong; Sun, Fenjin; Zhao, Linlin; Dun, Aishe; Sun, Zilin

doi:10.1007/s00011-015-0850-9

Cited by 49 publications

(41 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The risk allele for IL6 rs1800795 our study was C. This is in agreement with another study carried out in high-risk Pakistani families where the minor allele C showed high prevalence in cases compared with controls 10. While a strong association of the risk allele C was demonstrated with CAD in the Chinese18 and Indians23 no such association was seen in the Tunisians 24. The Northwick Park Heart study on the other hand showed that the IL6 rs1800795 GC (heterozygotes) were significantly at a greater risk to develop CAD as compared with the CC homozygotes 25.…”

Section: Discussionsupporting

confidence: 92%

“…Addressing this will require the discovery of additional loci to identify the molecular pathways underlying the pathogenesis of CAD. The cytokine gene promoter SNPs in our study were selected after a thorough literature search and from extensive meta-analyses18 47 which is considered to be the gold standard for SNP selection 12. Recent genome wide association studies and meta-analyses have identified cytokine genes and their variants (IL-18, IL-10, IL-6 and TNFA) as the potential CAD risk loci some of which significantly affect the serum cytokine levels 44 48 49.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of cytokine gene polymorphisms on proinflammatory/anti-inflammatory cytokine imbalance in premature coronary artery disease

Ansari

Humphries

Naveed

et al. 2016

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Influence of cytokine gene polymorphisms on proinflammatory/anti-inflammatory cytokine imbalance in premature coronary artery disease

Ansari

Humphries

Naveed

et al. 2016

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

“…Furthermore, the scope of our review did not account for the possible contribution of genetic variations leading to genetic predisposition of different ethnic groups and different HCV genotypes to CVD outcomes. In particular polymorphisms in cytokine genes or promoter regions may affect expression of inflammatory mediators and hence may affect CVD risk . Studies investigating genetic associations with inflammatory markers have been inconclusive and were not considered in the scope of this review.…”

Section: Discussionmentioning

confidence: 99%

Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review

Babiker

Hassan

Muhammed

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infects 180 million people worldwide and over 4 million people in the United States. HCV infection is a major cause of chronic liver disease and is recognized as a risk factor for clinical cardiovascular disease (CVD). Many studies have shown increased prevalence of cardiac and inflammatory biomarkers in patients with chronic HCV infection (CHC), and though these markers may be used to risk stratify people for cardiac disease in the general population their role in the HCV population is unknown. Patients with CHC have elevated cardiac and inflammatory biomarkers compared to noninfected controls which may play a role in CVD risk stratification. We undertook a systematic review of inflammatory and cardiac biomarkers in people with HCV infection with a focus on the effect of CHC on serum levels of these markers and their utility as predictors of CVD in this population. Medline, EMBASE, and Cochrane databases were searched for relevant articles until June 2019. A total of 2430 results were reviewed with 115 studies included. Our review revealed that HCV infection significantly alters serum levels of markers of inflammation, endothelial function, and cardiac dysfunction prior to HCV treatment, and some of which may change in response to HCV therapy. Current risk stratification tools for development of CVD in the general population may not account for the increased inflammatory markers that appear to be elevated among HCV‐infected patients contributing to increased CVD risk.

show abstract

“…Carriers of the−174G > C mutation have an increased risk of developing various major diseases, including Alzheimer disease 30 , CVD 31 , non-insulin-dependent diabetes mellitus 32 , bone fragility 33 , and systemic-onset juvenile chronic arthritis 34 . A genome-wide association study comparing >2,000 Chinese centenarians to middle-aged controls found that the SNP rs2069837 in IL6 was significantly associated with extreme longevity, confirming the role of IL-6 in conditioning morbidity and mortality, especially in old age 35 .…”

Section: Risk Factors and Causes Of Inflammageingmentioning

confidence: 99%

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty

2018

View full text Add to dashboard Cite

Most older individuals develop inflammageing, a condition characterized by elevated levels of blood inflammatory markers that carries high susceptibility to chronic morbidity, disability, frailty, and premature death. Potential mechanisms of inflammageing include genetic susceptibility, central obesity, increased gut permeability, changes to microbiota composition, cellular senescence, NLRP3 inflammasome activation, oxidative stress caused by dysfunctional mitochondria, immune cell dysregulation, and chronic infections. Inflammageing is a risk factor for cardiovascular diseases (CVDs), and clinical trials suggest that this association is causal. Inflammageing is also a risk factor for chronic kidney disease, diabetes mellitus, cancer, depression, dementia, and sarcopenia, but whether modulating inflammation beneficially affects the clinical course of non-CVD health problems is controversial. This uncertainty is an important issue to address because older patients with CVD are often affected by multimorbidity and frailty — which affect clinical manifestations, prognosis, and response to treatment — and are associated with inflammation by mechanisms similar to those in CVD. The hypothesis that inflammation affects CVD, multimorbidity, and frailty by inhibiting growth factors, increasing catabolism, and interfering with homeostatic signalling is supported by mechanistic studies but requires confirmation in humans. Whether early modulation of inflammageing prevents or delays the onset of cardiovascular frailty should be tested in clinical trials.

show abstract

Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis

Abstract: The C allele of -174G/C polymorphism may associate with increased sensibility to CAD among Caucasians in overall analysis. Nevertheless, the effect is interfered by heterogeneity across the included studies. The C allele of -572G/C polymorphism may decrease the risk of CAD in Chinese.

Cited by 49 publications

References 49 publications

Influence of cytokine gene polymorphisms on proinflammatory/anti-inflammatory cytokine imbalance in premature coronary artery disease

Influence of cytokine gene polymorphisms on proinflammatory/anti-inflammatory cytokine imbalance in premature coronary artery disease

Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty

Contact Info

Product

Resources

About